Monoclonal antibodies against psoriasis
A drug, still under study by Johnson & Johnson shows positive effects that bode well against psoriasis , one of the most common forms of chronic dermatitis in the world. The news reported from a phase 3 study of Ustekinumab (CNTO 1275) shows a significant reduction, quantified around 75% (data obtained by measuring the affected… Continua a leggere Monoclonal antibodies against psoriasis
2022-12-28Marketing